Update from Aluf Holdings Inc. on Forthcoming Acquisition of Nanomatronix, LLC
Aluf Holdings, Inc. (OTC PINK:AHIX) is progressing towards the acquisition of Nanomatronix (NMX), expected to close by the end of 2024. The company is focusing on three key technology areas:
1. Microelectronics Screening and Qualification Testing: NMX has ongoing contracts for optoelectronics subsystems screening for US satellites and defense platforms.
2. Biological Technologies: NMX is developing advanced Organ-on-Chip (OOC) solutions and Wound Healing Technologies, collaborating with University of Arkansas researchers.
3. Carbon Nanotube Technology (CNT): NMX has developed a unique approach to manufacturing ultra-long Carbon Nanotubes, potentially revolutionizing various industries.
Post-acquisition, NMX will become a wholly-owned subsidiary of Aluf Holdings, maintaining its status as a US-based, 100% US-owned, and US-sourced small business.
Aluf Holdings, Inc. (OTC PINK:AHIX) sta procedendo verso l'acquisizione di Nanomatronix (NMX), prevista per la conclusione entro la fine del 2024. L'azienda si sta concentrando su tre aree tecnologiche chiave:
1. Screening e Testing di Qualificazione per Microelettronica: NMX ha contratti in corso per lo screening di sottosistemi optoelettronici per satelliti e piattaforme di difesa americani.
2. Tecnologie Biologiche: NMX sta sviluppando avanzate soluzioni Organ-on-Chip (OOC) e tecnologie per la guarigione delle ferite, collaborando con i ricercatori dell'Università dell'Arkansas.
3. Tecnologia dei Nanotubi di Carbonio (CNT): NMX ha sviluppato un approccio unico per la produzione di nanotubi di carbonio ultra-lunghi, potenzialmente in grado di rivoluzionare vari settori.
Dopo l'acquisizione, NMX diventerà una filiale interamente controllata di Aluf Holdings, mantenendo il suo status di piccola impresa interamente americana, 100% di proprietà degli Stati Uniti e con forniture statunitensi.
Aluf Holdings, Inc. (OTC PINK:AHIX) está avanzando hacia la adquisición de Nanomatronix (NMX), que se espera que se cierre a finales de 2024. La empresa se está concentrando en tres áreas tecnológicas clave:
1. Pruebas de Selección y Calificación en Microelectrónica: NMX tiene contratos en curso para la selección de subsistemas optoelectrónicos para satélites estadounidenses y plataformas de defensa.
2. Tecnologías Biológicas: NMX está desarrollando soluciones avanzadas de Organ-on-Chip (OOC) y tecnologías de cicatrización de heridas, colaborando con investigadores de la Universidad de Arkansas.
3. Tecnología de Nanotubos de Carbono (CNT): NMX ha desarrollado un enfoque único para la fabricación de nanotubos de carbono ultra-largos, potencialmente revolucionando diversas industrias.
Tras la adquisición, NMX se convertirá en una subsidiaria de propiedad total de Aluf Holdings, manteniendo su estatus como una pequeña empresa con sede en EE. UU., 100% de propiedad estadounidense y con suministros de origen estadounidense.
Aluf Holdings, Inc. (OTC PINK:AHIX)는 2024년 말까지 완료될 예정인 Nanomatronix (NMX) 인수에 진전을 보이고 있습니다. 이 회사는 세 가지 주요 기술 분야에 집중하고 있습니다:
1. 반도체 스크리닝 및 검증 테스트: NMX는 미국 위성 및 방위 플랫폼을 위한 광전자 서브시스템 스크리닝에 대한 진행 중인 계약을 보유하고 있습니다.
2. 생물학적 기술: NMX는 아칸소 대학교의 연구자들과 협력하여 고급 Organ-on-Chip (OOC) 솔루션 및 상처 치유 기술을 개발하고 있습니다.
3. 탄소 나노튜브 기술 (CNT): NMX는 다양한 산업을 혁신할 수 있는 초긴 탄소 나노튜브 제조를 위한 독특한 접근 방식을 개발했습니다.
인수 후 NMX는 Aluf Holdings의 전액 출자 자회사가 되며, 미국 기반, 100% 미국 소유 및 미국 공급의 소기업으로서 지위를 유지하게 됩니다.
Aluf Holdings, Inc. (OTC PINK:AHIX) progresse vers l'acquisition de Nanomatronix (NMX), qui devrait se conclure d'ici la fin de l'année 2024. L'entreprise se concentre sur trois domaines technologiques clés :
1. Tests de Sélection et de Qualification en Microélectronique: NMX a des contrats en cours pour le test de sous-systèmes optoélectroniques destinés aux satellites américains et aux plateformes de défense.
2. Tecnologies Biologiques: NMX développe des solutions avancées Organ-on-Chip (OOC) et des technologies de cicatrisation des plaies, en collaboration avec des chercheurs de l'Université de l'Arkansas.
3. Technologie des Nanotubes de Carbone (CNT): NMX a développé une approche unique pour la fabrication de nanotubes de carbone ultra-longs, susceptible de révolutionner divers secteurs.
Après l'acquisition, NMX deviendra une filiale entièrement détenue d'Aluf Holdings, conservant son statut de petite entreprise basée aux États-Unis, entièrement américaine et approvisionnée aux États-Unis.
Aluf Holdings, Inc. (OTC PINK:AHIX) macht Fortschritte beim Erwerb von Nanomatronix (NMX), dessen Abschluss bis Ende 2024 erwartet wird. Das Unternehmen konzentriert sich auf drei zentrale Technologiebereiche:
1. Mikroelektronik Screening und Qualifikationstests: NMX hat laufende Verträge für das Screening von optoelektronischen Subsystemen für US-Satelliten und Verteidigungsplattformen.
2. Biologische Technologien: NMX entwickelt fortschrittliche Organ-on-Chip (OOC) Lösungen und Wundheiltechnologien in Zusammenarbeit mit Forschern der University of Arkansas.
3. Kohlenstoff-Nanoröhren-Technologie (CNT): NMX hat einen einzigartigen Ansatz zur Herstellung ultra-langer Kohlenstoffnanoröhren entwickelt, der möglicherweise verschiedene Industrien revolutionieren könnte.
Nach der Übernahme wird NMX ein vollständig im Besitz von Aluf Holdings befindliches Tochterunternehmen werden und seinen Status als US-amerikanisches, zu 100 % in US-Besitz befindliches und aus den USA bezogenes Kleinunternehmen beibehalten.
- Acquisition of Nanomatronix (NMX) expected to close by end of 2024, expanding Aluf Holdings' technological capabilities
- Existing contracts with major DOD primes for microelectronics screening and qualification testing
- Development of advanced Organ-on-Chip (OOC) solutions and Wound Healing Technologies
- Unique manufacturing process for ultra-long Carbon Nanotubes (UL-CNTs), potentially revolutionizing multiple industries
- Flexible staffing model with up to 12 full-time employees and 24 PhD-level technical partners, limiting operational costs
- Acquisition completion still pending, subject to potential delays or complications
- Heavy reliance on government and defense contracts, which can be subject to budget fluctuations and political changes
- R&D-intensive business model with multiple early-stage technologies, implying significant ongoing investment requirements
FORT LAUDERDALE, FL / ACCESSWIRE / October 3, 2024 / ALUF Holdings, Inc. (OTC PINK:AHIX) Acting CEO and Director, Joseph Paresi, is pleased to announce that detailed planning and execution discussions have occurred with Aluf's new Chief Operating and Chief Technology Officer (COO/CTO), Dr. Matthew Leftwich, regarding the integration of existing contracts and new business opportunities, as the team moves toward accelerating the planned acquisition closing of Nanomatronix (NMX) before the end of 2024.
The near-term technology focus of Aluf and NMX has been on three key areas:
Microelectronics Screening and Qualification Testing - Continuation of the present NMX contracts for screening and qualification of optoelectronics subsystems in support of the USG plan to upgrade US satellites and other defense platforms. Screening begins in 2024 on two (2) multi-phase contracts with major DOD primes. Additional contract mechanisms with Defense, Aerospace, and Satellite providers have been identified and plans to pursue them have been established.
Biological Technologies - NMX has existing contracts with several pending and scheduled to begin within six months. These involve unique advancements in Biological Technologies (aka: Biotech) focused in two main areas - Advanced Organ-on-Chip (OOC) solutions and Wound Healing Technologies in collaboration with certain faculty of the University of Arkansas based on the unique inventions of (6) six key UA researchers.
Organ-on-chip (OOC) technologies involve microfluidic cell culture chips that mimic the functions, mechanics, and physiological responses of an organ, or organ system. The key discriminator differentiating NMX technologies from competitive approaches is the ability to measure Trans-epithelial/Trans-endothelial Electrical Resistance (TEER), a major discriminator in analyzing drug effects on live tissue. Other optical sensing mechanisms are being added for additional flow study capability that further differentiates NMX tech over their primary competitor in this space.
NMX is targeting three initial areas of OOC product releases: Advanced Micro-physiological Brain Injury Technology (AMBIT), for TBI studies and drug/treatment development; Nasal Airway Chips (NAC), to perform epidemiological studies of particle effects on the respiratory system and drug/treatment development; and Heart Valve Organ Chips (HaVOC), to study and develop treatments for diseases and conditions associated with Heart Valve issues.
Wound Healing efforts are focused on three initial enabling technologies: Gold Nano-constructs for Infection Remediation (AuNIR), aimed at combating drug-resistant infections; Injectable matrix Gels (InMaG), initially aimed at repairing degenerated rotator cuff muscles; and Fibroblast Injectable Anionic Hydrogels (FLIAH/shFGF1), aimed at healing diabetic induced skin wounds.
Carbon Nanotube Technology (CNT) - Dr. Leftwich has developed a unique approach to manufacturing ultra-long Carbon Nanotubes (UL-CNTs) as an advanced technology for the next generation of high strength-to-weight ratio materials and advanced x-ray sources. Specifically, longer length carbon nanotubes are expected to be an upgrade to a broad range of carbon fiber solutions. Further, NMX has developed a process to manufacture CNT material in lengths over twenty times (20x) longer than existing approaches, enabling CNT-based applications not yet realized. CNT-based composites have tensile strength over 10 times greater than existing carbon fiber composites and reveal significant improvements in strength-to-weight ratio that could allow for significant improvements in aircraft, structural, and multi-functional materials. R&D is ramping-up to extend pure CNT lengths beyond 1 cm (post-harvest) for direct integration into novel CNT-composites.
The numerous advantages of this material will apply to advancement in defense and aerospace applications including aircraft, drones, missiles, armored vehicles, commercial vehicles, and bullet-proof materials, amongst others, as well as a solid-state solution to replace costly and less reliable x-ray technologies as used in medical, security and manufacturing, including non-destructive testing.
Pending Acquisition of Nanomatronix, LLC:
NMX operates by using a flexible staff comprised of up to twelve full-time employees, augmented by up to twenty-four PhD level technical partners, and their research centers, which have created ideal channels for recruiting new talent from the UA and partnering institutions. This arrangement allows for technology development in a wide range of areas while limiting operational costs and benefiting UA students with real-life research and development opportunities.
ALUF Holdings will manage all back-office functions, including finance and accounting, legal, marketing, and human resources as part of the acquisition agreement with NMX, scheduled to close by the end of 2024. Implementation of production programs for the above technologies will involve a combination of ALUF/NMX-produced manufacturing, augmented by go-to-market partnerships specific to the technical operational areas as appropriate.
Aluf Holdings has signed a purchase agreement to acquire NMX, with the deal expected to close by the end of 2024. Dr. Leftwich will play a key role in expanding the company's research and development (R&D) and technology growth strategies, with primary R&D operations based in Fayetteville, AR. Upon completion of the acquisition, NMX will become a wholly owned subsidiary of Aluf Holdings, Inc., maintaining its status as a US-based,
About Aluf Holdings, Inc.:
Aluf Holdings, Inc., a publicly traded company dedicated to acquiring, developing, and managing a diverse portfolio of high-growth-potential companies and technologies. With a strong focus on the biotech and biometrics industries, Aluf aims to revolutionize these sectors through innovative solutions and strategic acquisitions. An acquisition roadmap, including several fully executed Stock Purchase Agreements (SPAs) has been signed as Aluf Holdings, Inc. expands its operational structure in key and well-established markets, comprised of several companies that have strong operational and financial performance.
About Nanomatronix, LLC:
Nanomatronix, LLC (NMX) is a US-based small business specializing in
Contact Information:
Joseph Paresi, CEO
Aluf Holdings, Inc.
914-643-5251
jparesi@aluf.com
jparesi@tasktmc.com
Teresa McWilliams, CFO
Aluf Holdings, Inc.
teresa.mcwilliams@aluf.com
866-793-1110
Dr. Matt Leftwich, Ph.D.
CTO/COO - Aluf Holdings, Inc.
matt.leftwich@aluf.com
CEO/Engineering Director - Nanomatronix, LLC
mleftwich@nanomatronix.com
Safe Harbor Statement:
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate and are subject to significant risks and uncertainties. Factors that could cause actual results to differ include, but are not limited to, the company's ability to secure financing, retain key personnel, ensure timely delivery of inventory, and develop and market new products. The company disclaims any intention or obligation to update forward-looking statements as a result of developments occurring after the date of this release.
SOURCE: Aluf Holdings, Inc.
View the original press release on accesswire.com
FAQ
What is the expected closing date for Aluf Holdings' (AHIX) acquisition of Nanomatronix?
What are the three key technology areas Aluf Holdings (AHIX) is focusing on with the Nanomatronix acquisition?
How will the Nanomatronix acquisition impact Aluf Holdings' (AHIX) business structure?
What unique technology has Nanomatronix developed in Carbon Nanotube manufacturing for Aluf Holdings (AHIX)?
